Gut microbiota, immunity, and bile acid metabolism: decoding metabolic disease interactions

Abstract

In recent decades, the global prevalence of metabolic syndrome has surged, posing a significant public health challenge. Metabolic disorders, encompassing diabetes, obesity, nonalcoholic fatty liver disease, and polycystic ovarian syndrome, have been linked to alterations in the gut microbiota. Nonetheless, the connection between gut microbiota and host metabolic diseases warrants further investigation. In this review, we delve into the associations between various metabolic disorders and the gut microbiota, focusing on immune responses and bile acid (BA) metabolism. Notably, T helper cells, innate lymphoid cells, macrophages, and dendritic cells have been shown to modulate host metabolism through interactions with intestinal microorganisms and the release of cytokines. Furthermore, secondary BA metabolites, derived from the microbiota, are involved in the pathogenesis of metabolic diseases via the farnesoid X receptor and Takeda G protein-coupled receptor 5. By covering both aspects of this immune system-microorganism axis, we present a comprehensive overview of the roles played by the gut microbiota, microbiota-derived BA metabolites, and immune responses in metabolic diseases, as well as the interplay between these systems.

Key words： intestinal microbiota; metabolic disease; immunity; bile acids

References

1 Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415–28.

2 Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med 2016;375:2369–79.

3 Qin J, Li Y, Cai Z et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012;490:55–60.

4 Li F, Jiang C, Krausz KW et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun 2013;4:2384.

5 Demir M, Lang S, Hartmann P et al. The fecal mycobiome in non-alcoholic fatty liver disease. J Hepatol 2022;76:788–99.

6 Qi X, Yun C, Sun L et al. Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome. Nat Med 2019;25:1225–33.

7 Collins SL, Stine JG, Bisanz JE et al. Bile acids and the gut microbiota: metabolic interactions and impacts on disease. Nat Rev Microbiol 2022;21:236–47.

8 Cai J, Sun L, Gonzalez FJ. Gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumorigenesis. Cell Host Microbe 2022;30:289–300.

9 Zheng X, Chen T, Jiang R et al. Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism. Cell Metab 2021;33:791–803.e7.

10 Jiang C, Xie C, Li F et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest 2015;125:386–402.

11 Gonzalez FJ, Jiang C, Patterson AD. An intestinal microbiota-farnesoid X receptor axis modulates metabolic disease. Gastroenterology 2016;151:845–59.

12 Jiang C, Xie C, Lv Y et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun 2015;6:10166.

13 Kawano Y, Edwards M, Huang Y et al. Microbiota imbalance induced by dietary sugar disrupts immune-mediated protection from metabolic syndrome. Cell 2022;185:3501–19.e20.

14 Thingholm LB, Rühlemann MC, Koch M et al. Obese individuals with and without type 2 diabetes show different gut microbial functional capacity and composition. Cell Host Microbe 2019;26:252–64.e10.

15 Yang G, Wei J, Liu P et al. Role of the gut microbiota in type 2 diabetes and related diseases. Metabolism 2021;117:154712.

16 Karlsson FH, Tremaroli V, Nookaew I et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013;498:99–103.

17 Everard A, Lazarevic V, Derrien M et al. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 2011;60:2775–86.

18 Santacruz A, Collado MC, García-Valdés L et al. Gut microbiota composition is associated with body weight, weight gain and biochemical parameters in pregnant women. Br J Nutr 2010;104:83–92.

19 Karlsson CL, Onnerfält J, Xu J et al. The microbiota of the gut in preschool children with normal and excessive body weight. Obesity (Silver Spring) 2012;20:2257–61.

20 Everard A, Belzer C, Geurts L et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A 2013;110:9066–71.

21 Depommier C, Everard A, Druart C et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med 2019;25:1096–103.

22 Plovier H, Everard A, Druart C et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med 2017;23:107–13.

23 Zhang J, Ni Y, Qian L et al. Decreased abundance of Akkermansia muciniphila leads to the impairment of insulin secretion and glucose homeostasis in lean type 2 diabetes. Adv Sci (Weinh) 2021;8:e2100536.

24 Pedret A, Valls RM, Calderón-Pérez L et al. Effects of daily consumption of the probiotic Bifidobacterium animalis subsp. lactis CECT 8145 on anthropometric adiposity biomarkers in abdominally obese subjects: a randomized controlled trial. Int J Obes (Lond) 2019;43:1863–8.

25 Mcallister EJ, Dhurandhar NV, Keith SW et al. Ten putative contributors to the obesity epidemic. Crit Rev Food Sci Nutr 2009;49:868–913.

26 Cox LM, Blaser MJ. Antibiotics in early life and obesity. Nat Rev Endocrinol 2015;11:182–90.

27 Wilkins AT, Reimer RA. Obesity, early life gut microbiota, and antibiotics. Microorganisms 2021;9:413.

28 Bailey LC, Forrest CB, Zhang P et al. Association of antibiotics in infancy with early childhood obesity. JAMA Pediatr 2014;168:1063–9.

29 Turnbaugh PJ, Ley RE, Mahowald MA et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027–31.

30 Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol 2021;19:55–71.

31 Gophna U, Konikoff T, Nielsen HB. Oscillospira and related bacteria - from metagenomic species to metabolic features. Environ Microbiol 2017;19:835–41.

32 Miller TL, Wolin MJ, Conway de Macario E et al. Isolation of Methanobrevibacter smithii from human feces. Appl Environ Microbiol 1982;43:227–32.

33 Tims S, Derom C, Jonkers DM et al. Microbiota conservation and BMI signatures in adult monozygotic twins. ISME J 2013;7:707–17.

34 Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol 2015;11:577–91.

35 Abenavoli L, Scarpellini E, Colica C et al. Gut microbiota and obesity: a role for probiotics. Nutrients 2019;11:2690.

36 Ley RE, Bäckhed F, Turnbaugh P et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005;102:11070–5.

37 Zuo HJ, Xie ZM, Zhang WW et al. Gut bacteria alteration in obese people and its relationship with gene polymorphism. World J Gastroenterol 2011;17:1076–81.

38 Schwiertz A, Taras D, Schäfer K et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring) 2010;18:190–5.

39 Brunt EM, Kleiner DE, Wilson LA et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011;53:810–20.

40 Younossi ZM, Koenig AB, Abdelatif D et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73–84.

41 Compare D, Coccoli P, Rocco A et al. Gut–liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2012;22:471–6.

42 Jiang W, Wu N, Wang X et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep 2015;5:8096.

43 Zhu L, Baker SS, Gill C et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013;57:601–9.

44 Oh TG, Kim SM, Caussy C et al. A universal gut-microbiome-derived signature predicts cirrhosis. Cell Metab 2020;32:901.

45 Wang T, Guo XK, Xu H. Disentangling the progression of non-alcoholic fatty liver disease in the human gut microbiota. Front Microbiol 2021;12:728823.

46 Chen B, Sun L, Zeng G et al. Gut bacteria alleviate smoking-related NASH by degrading gut nicotine. Nature 2022;610:562–8.

47 Lee G, You HJ, Bajaj JS et al. Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in nonobese NAFLD. Nat Commun 2020;11:4982.

48 Nair S, Cope K, Risby TH et al. Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:1200–4.

49 Dawes EA, Foster SM. The formation of ethanol in Escherichia coli. Biochim Biophys Acta 1956;22:253–65.

50 Torres PJ, Siakowska M, Banaszewska B et al. Gut microbial diversity in women with polycystic ovary syndrome correlates with hyperandrogenism. J Clin Endocrinol Metab 2018;103:1502–11.

51 Insenser M, Murri M, Del Campo R et al. Gut microbiota and the polycystic ovary syndrome: influence of sex, sex hormones, and obesity. J Clin Endocrinol Metab 2018;103:2552–62.

52 Liu R, Zhang C, Shi Y et al. Dysbiosis of gut microbiota associated with clinical parameters in polycystic ovary syndrome. Front Microbiol 2017;8:324.

53 Zhou L, Ni Z, Cheng W et al. Characteristic gut microbiota and predicted metabolic functions in women with PCOS. Endocr Connect 2020;9:63–73.

54 Guo J, Shao J, Yang Y et al. Gut microbiota in patients with polycystic ovary syndrome: a systematic review. Reprod Sci 2022;29:69–83.

55 Ley RE. Gut microbiota in 2015: Prevotella in the gut: choose carefully. Nat Rev Gastroenterol Hepatol 2016;13:69–70.

56 Guo Y, Qi Y, Yang X et al. Association between polycystic ovary syndrome and gut microbiota. PLoS One 2016;11:e0153196.

57 Sherman SB, Sarsour N, Salehi M et al. Prenatal androgen exposure causes hypertension and gut microbiota dysbiosis. Gut Microbes 2018;9:400–21.

58 Hofer U. Microbiome: pro-inflammatory Prevotella? Nat Rev Microbiol 2014;12:5.

59 Jiang L, Shang M, Yu S et al. A high-fiber diet synergizes with Prevotella copri and exacerbates rheumatoid arthritis. Cell Mol Immunol 2022;19:1414–24.

60 Zhao Q, Yu J, Zhou H et al. Intestinal dysbiosis exacerbates the pathogenesis of psoriasis-like phenotype through changes in fatty acid metabolism. Signal Transduct Target Ther 2023;8:40.

61 Matsubara T, Li F, Gonzalez FJ. FXR signaling in the enterohepatic system. Mol Cell Endocrinol 2013;368:17–29.

62 Cai J, Rimal B, Jiang C et al. Bile acid metabolism and signaling, the microbiota, and metabolic disease. Pharmacol Ther 2022;237:108238.

63 Forman BM, Goode E, Chen J et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995;81:687–93.

64 Makishima M, Okamoto AY, Repa JJ et al. Identification of a nuclear receptor for bile acids. Science 1999;284:1362–5.

65 Parks DJ, Blanchard SG, Bledsoe RK et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999;284:1365–8.

66 Sinal CJ, Tohkin M, Miyata M et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000;102:731–44.

67 Cariou B, van Harmelen K, Duran-Sandoval D et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 2006;281:11039–49.

68 Prawitt J, Abdelkarim M, Stroeve JHM et al. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 2011;60:1861–71.

69 Sun L, Cai J, Gonzalez FJ. The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer. Nat Rev Gastroenterol Hepatol 2021;18:335–47.

70 Jiang J, Ma Y, Liu Y et al. Glycine-β-muricholic acid antagonizes the intestinal farnesoid X receptor-ceramide axis and ameliorates NASH in mice. Hepatol Commun 2022;6:3363–78.

71 Fang S, Suh JM, Reilly SM et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 2015;21:159–65.

72 Pathak P, Xie C, Nichols RG et al. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism. Hepatology 2018;68:1574–88.

73 Gillard J, Picalausa C, Ullmer C et al. Enterohepatic Takeda G-protein coupled receptor 5 agonism in metabolic dysfunction-associated fatty liver disease and related glucose dysmetabolism. Nutrients 2022;14:2707.

74 Zhang Y, Jackson JP, St. Claire RL et al. Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich-cultured human hepatocytes. Pharmacol Res Perspect 2017;5:e00329.

75 Nevens F, Andreone P, Mazzella G et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 2016;375:631–43.

76 Chapman RW, Lynch KD. Obeticholic acid-a new therapy in PBC and NASH. Br Med Bull 2020;133:95–104.

77 Fickert P, Hirschfield GM, Denk G et al. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol 2017;67:549–58.

78 Zhu C, Boucheron N, Rica R et al. 24-Nor-ursodeoxycholic acid counteracts TH17/Treg imbalance and ameliorates intestinal inflammation by restricting glutaminolysis in differentiating TH17 cells. bioRxiv, 2022.

79 Nakajima A, Seki M, Taniguchi S et al. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. Lancet Gastroenterol Hepatol 2018;3:537–47.

80 Pathak P, Liu H, Boehme S et al. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism. J Biol Chem 2017;292:11055–69.

81 Chiang JYL, Ferrell JM. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. Am J Physiol Gastrointest Liver Physiol 2020;318:G554–73.

82 Thomas C, Gioiello A, Noriega L et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009;10:167–77.

83 Makki K, Brolin H, Petersen N et al. 6α-hydroxylated bile acids mediate TGR5 signalling to improve glucose metabolism upon dietary fiber supplementation in mice. Gut 2023;72:314–24.

84 Wu Q, Liang X, Wang K et al. Intestinal hypoxia-inducible factor 2α regulates lactate levels to shape the gut microbiome and alter thermogenesis. Cell Metab 2021;33:1988–2003.e7.

85 Castellanos-Jankiewicz A, Guzmán-Quevedo O, Fénelon VS et al. Hypothalamic bile acid-TGR5 signaling protects from obesity. Cell Metab 2021;33:1483–92.e10.

86 Fang Y, Han SI, Mitchell C et al. Bile acids induce mitochondrial ROS, which promote activation of receptor tyrosine kinases and signaling pathways in rat hepatocytes. Hepatology 2004;40:961–71.

87 Ratziu V, de Ledinghen V, Oberti F et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 2011;54:1011–9.

88 Tsuchida T, Shiraishi M, Ohta T et al. Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice. Metabolism 2012;61:944–53.

89 Chen YS, Liu HM, Lee TY. Ursodeoxycholic acid regulates hepatic energy homeostasis and white adipose tissue macrophages polarization in leptin-deficiency obese mice. Cells 2019;8:253.

90 Liu J, Wei Y, Jia W et al. Chenodeoxycholic acid suppresses AML progression through promoting lipid peroxidation via ROS/p38 MAPK/DGAT1 pathway and inhibiting M2 macrophage polarization. Redox Biol 2022;56:102452.

91 Thaiss CA, Zmora N, Levy M et al. The microbiome and innate immunity. Nature 2016;535:65–74.

92 Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease. Nature 2016;535:75–84.

93 Odegaard JI, Chawla A. Alternative macrophage activation and metabolism. Annu Rev Pathol 2011;6:275–97.

94 Weisberg SP, McCann D, Desai M et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796–808.

95 Lumeng CN, DelProposto JB, Westcott DJ et al. Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes 2008;57:3239–46.

96 Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007;117:175–84.

97 Lumeng CN, Deyoung SM, Saltiel AR. Macrophages block insulin action in adipocytes by altering expression of signaling and glucose transport proteins. Am J Physiol Endocrinol Metab 2007;292:E166–74.

98 Odegaard JI, Ricardo-Gonzalez RR, Goforth MH et al. Macrophage-specific PPARγ controls alternative activation and improves insulin resistance. Nature 2007;447:1116–20.

99 Chawla A, Nguyen KD, Goh YP. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol 2011;11:738–49.

100 Pan Y, Suga A, Kimura I et al. Cyclooxygenase-2 in adipose tissue macrophages limits adipose tissue dysfunction in obese mice. J Clin Invest 2022;132:e153589.

101 Krenkel O, Tacke F. Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol 2017;17:306–21.

102 Huby T, Gautier EL. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat Rev Immunol 2022;22:429–43.

103 Jaitin DA, Adlung L, Thaiss CA et al. Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner. Cell 2019;178:686–98.e14.

104 Hou J, Zhang J, Cui P et al. TREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis. J Clin Invest 2021;131:e135197.

105 Wang X, He Q, Zhou C et al. Prolonged hypernutrition impairs TREM2-dependent efferocytosis to license chronic liver inflammation and NASH development. Immunity 2022;56:58–77.e11.

106 Li X, Zhang X, Xia J et al. Macrophage HIF-2α suppresses NLRP3 inflammasome activation and alleviates insulin resistance. Cell Rep 2021;36:109607.

107 Lian G, Li X, Zhang L et al. Macrophage metabolic reprogramming aggravates aortic dissection through the HIF1α-ADAM17 pathway^☆. EBioMedicine 2019;49:291–304.

108 Sell H, Habich C, Eckel J. Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol 2012;8:709–16.

109 Winer S, Chan Y, Paltser G et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med 2009;15:921–9.

110 Rocha VZ, Folco EJ, Sukhova G et al. Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. Circ Res 2008;103:467–76.

111 Winer S, Paltser G, Chan Y et al. Obesity predisposes to Th17 bias. Eur J Immunol 2009;39:2629–35.

112 Zuniga LA, Shen WJ, Joyce-Shaikh B, et al. IL-17 regulates adipogenesis, glucose homeostasis, and obesity. J Immunol 2010;185:6947–59.

113 Chen Y, Tian J, Tian X et al. Adipose tissue dendritic cells enhances inflammation by prompting the generation of Th17 cells. PLoS One 2014;9:e92450.

114 Cavallari JF, Denou E, Foley KP et al. Different Th17 immunity in gut, liver, and adipose tissues during obesity: the role of diet, genetics, and microbes. Gut Microbes 2016;7:82–9.

115 Garidou L, Pomié C, Klopp P et al. The gut microbiota regulates intestinal CD4 T cells expressing RORγt and controls metabolic disease. Cell Metab 2015;22:100–12.

116 Cox LM, Yamanishi S, Sohn J et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell 2014;158:705–21.

117 Feuerer M, Herrero L, Cipolletta D et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 2009;15:930–9.

118 Deiuliis J, Shah Z, Shah N et al. Visceral adipose inflammation in obesity is associated with critical alterations in tregulatory cell numbers. PLoS One 2011;6:e16376.

119 Cipolletta D, Kolodin D, Benoist C et al. Tissular T_regs: a unique population of adipose-tissue-resident Foxp3₊CD4₊ T cells that impacts organismal metabolism. Semin Immunol 2011;23:431–7.

120 Yuan N, Zhang H-F, Wei Q et al. Expression of CD4₊CD25₊Foxp3₊ regulatory T cells, interleukin 10 and transforming growth factor β in newly diagnosed type 2 diabetic patients. Exp Clin Endocrinol Diabetes 2018;126:96–101.

121 Wagner NM, Brandhorst G, Czepluch F et al. Circulating regulatory T cells are reduced in obesity and may identify subjects at increased metabolic and cardiovascular risk. Obesity (Silver Spring) 2013;21:461–8.

122 Gyllenhammer LE, Lam J, Alderete TL et al. Lower omental t-regulatory cell count is associated with higher fasting glucose and lower β-cell function in adults with obesity. Obesity (Silver Spring) 2016;24:1274–82.

123 Ramadori P, Kam S, Heikenwalder M. T cells: friends and foes in NASH pathogenesis and hepatocarcinogenesis. Hepatology 2022;75:1038–49.

124 Bhattacharjee J, Kirby M, Softic S et al. Hepatic natural killer T-cell and CD8⁺ T-cell signatures in mice with nonalcoholic steatohepatitis. Hepatol Commun 2017;1:299–310.

125 Breuer DA, Pacheco MC, Washington MK et al. CD8⁺ T cells regulate liver injury in obesity-related nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol 2020;318:G211–24.

126 Inzaugarat ME, Ferreyra Solari NE, Billordo LA et al. Altered phenotype and functionality of circulating immune cells characterize adult patients with nonalcoholic steatohepatitis. J Clin Immunol 2011;31:1120–30.

127 Sun G, Jin H, Zhang C et al. OX40 regulates both innate and adaptive immunity and promotes nonalcoholic steatohepatitis. Cell Rep 2018;25:3786–99.e4.

128 Su L, Wu Z, Chi Y et al. Mesenteric lymph node CD4⁺ T lymphocytes migrate to liver and contribute to non-alcoholic fatty liver disease. Cell Immunol 2019;337:33–41.

129 Rau M, Schilling AK, Meertens J et al. Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17/resting regulatory T cell ratio in peripheral blood and in the liver. J Immunol 2016;196:97–105.

130 Meng F, Wang K, Aoyama T et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 2012;143:765–776.e3.

131 Rappez L, Stadler M, Triana S et al. SpaceM reveals metabolic states of single cells. Nat Methods 2021;18:799–805.

132 Moreno-Fernandez ME, Giles DA, Oates JR et al. PKM2-dependent metabolic skewing of hepatic Th17 cells regulates pathogenesis of non-alcoholic fatty liver disease. Cell Metab 2021;33:1187–204.e9.

133 Li F, Hao X, Chen Y et al. The microbiota maintain homeostasis of liver-resident γδT-17 cells in a lipid antigen/CD1d-dependent manner. Nat Commun 2017;7:13839.

134 Yang Y, Xia J, Yang Z et al. The abnormal level of HSP70 is related to Treg/Th17 imbalance in PCOS patients. J Ovarian Res 2021;14:155.

135 Viel S, Besson L, Charrier E et al. Alteration of natural killer cell phenotype and function in obese individuals. Clin Immunol 2017;177:12–7.

136 Tobin LM, Mavinkurve M, Carolan E et al. NK cells in childhood obesity are activated, metabolically stressed, and functionally deficient. JCI Insight 2017;2:e94939.

137 Wensveen FM, Jelenčić V, Valentić S et al. NK cells link obesity-induced adipose stress to inflammation and insulin resistance. Nat Immunol 2015;16:376–85.

138 Lee BC, Kim M-S, Pae M et al. Adipose natural killer cells regulate adipose tissue macrophages to promote insulin resistance in obesity. Cell Metab 2016;23:685–98.

139 Kanda H, Tateya S, Tamori Y et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006;116:1494–505.

140 Bahr I, Spielmann J, Quandt D et al. Obesity-associated alterations of natural killer cells and immunosurveillance of cancer. Front Immunol 2020;11:245.

141 O’rourke RW, Gaston GD, Meyer KA et al. Adipose tissue NK cells manifest an activated phenotype in human obesity. Metabolism 2013;62:1557–61.

142 Ferno J, Strand K, Mellgren G et al. Natural killer cells as sensors of adipose tissue stress. Trends Endocrinol Metab 2020;31:3–12.

143 Bonamichi B, Lee J. Unusual suspects in the development of obesity-induced inflammation and insulin resistance: NK cells, iNKT cells, and ILCs. Diabetes Metab J 2017;41:229–50.

144 Stiglund N, Strand K, Cornillet M et al. Retained NK cell phenotype and functionality in non-alcoholic fatty liver disease. Front Immunol 2019;10:1255.

145 Theurich S, Tsaousidou E, Hanssen R et al. IL-6/Stat3-dependent induction of a distinct, obesity-associated NK cell subpopulation deteriorates energy and glucose homeostasis. Cell Metab 2017;26:171–84.e6.

146 Zhou L, Lin Q, Sonnenberg GF. Metabolic control of innate lymphoid cells in health and disease. Nat Metab 2022;4:1650–9.

147 Kim HY, Lee HJ, Chang YJ et al. Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. Nat Med 2014;20:54–61.

148 Wang X, Ota N, Manzanillo P et al. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature 2014;514:237–41.

149 Wang Y, Kuang Z, Yu X et al. The intestinal microbiota regulates body composition through NFIL3 and the circadian clock. Science 2017;357:912–6.

150 Sasaki T, Moro K, Kubota T et al. Innate lymphoid cells in the induction of obesity. Cell Rep 2019;28:202–17.e7.

151 Hamaguchi M, Okamura T, Fukuda T et al. Group 3 innate lymphoid cells protect steatohepatitis from high-fat diet induced toxicity. Front Immunol 2021;12:648754.

152 Ganguly D, Haak S, Sisirak V et al. The role of dendritic cells in autoimmunity. Nat Rev Immunol 2013;13:566–77.

153 Merad M, Sathe P, Helft J et al. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol 2013;31:563–604.

154 Bertola A, Ciucci T, Rousseau D et al. Identification of adipose tissue dendritic cells correlated with obesity-associated insulin-resistance and inducing Th17 responses in mice and patients. Diabetes 2012;61:2238–47.

155 Patsouris D, Li PP, Thapar D et al. Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab 2008;8:301–9.

156 Stefanovic-Racic M, Yang X, Turner MS et al. Dendritic cells promote macrophage infiltration and comprise a substantial proportion of obesity-associated increases in CD11c⁺ cells in adipose tissue and liver. Diabetes 2012;61:2330–9.

157 Macdougall CE, Wood EG, Loschko J et al. Visceral adipose tissue immune homeostasis is regulated by the crosstalk between adipocytes and dendritic cell subsets. Cell Metab 2018;27:588–601.e4.

158 Hernandez-Garcia E, Cueto FJ, Cook ECL et al. Conventional type 1 dendritic cells protect against age-related adipose tissue dysfunction and obesity. Cell Mol Immunol 2022;19:260–75.

159 Haas JT, Vonghia L, Mogilenko DA et al. Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution. Nat Metab 2019;1:604–14.

160 Deczkowska A, David E, Ramadori P et al. XCR1⁺ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis. Nat Med 2021;27:1043–54.

161 Galle-Treger L, Helou DG, Quach C et al. Autophagy impairment in liver CD11c⁺ cells promotes non-alcoholic fatty liver disease through production of IL-23. Nat Commun 2022;13:1440.

162 Winer DA, Luck H, Tsai S et al. The intestinal immune system in obesity and insulin resistance. Cell Metab 2016;23:413–26.

163 Bunker JJ, Bendelac A. IgA responses to microbiota. Immunity 2018;49:211–24.

164 Luck H, Khan S, Kim JH et al. Gut-associated IgA⁺ immune cells regulate obesity-related insulin resistance. Nat Commun 2019;10:3650.

165 Amar J, Chabo C, Waget A et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med 2011;3:559–72.

166 Cani PD, Bibiloni R, Knauf C et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008;57:1470–81.

167 Cani PD, Amar J, Iglesias MA et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007;56:1761–72.

168 Petersen C, Bell R, Klag KA et al. T cell-mediated regulation of the microbiota protects against obesity. Science 2019;365:eaat9351.

169 Hong CP, Park A, Yang BG et al. Gut-specific delivery of T-helper 17 cells reduces obesity and insulin resistance in mice. Gastroenterology 2017;152:1998–2010.

170 Shin NR, Lee JC, Lee HY et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 2014;63:727–35.

171 Zhao Q, Yu J, Hao Y et al. Akkermansia muciniphila plays critical roles in host health. Crit Rev Microbiol 2022;49:82–100.

172 Barcena C, Valdés-Mas R, Mayoral P et al. Healthspan and lifespan extension by fecal microbiota transplantation into progeroid mice. Nat Med 2019;25:1234–42.

173 Li J, Lin S, Vanhoutte PM et al. Akkermansia muciniphila protects against atherosclerosis by preventing metabolic endotoxemia- induced inflammation in Apoe^-/- mice. Circulation 2016;133:2434–46.

174 Wang J, Xu W, Wang R et al. The outer membrane protein Amuc_1100 of Akkermansia muciniphila promotes intestinal 5-HT biosynthesis and extracellular availability through TLR2 signalling. Food Funct 2021;12:3597–610.

175 Si J, Zhang H, Zhu L et al. The relationship between overweight/obesity and executive control in college students: the mediating effect of BDNF and 5-HT. Life (Basel) 2021;11:313.

176 Goto Y, Panea C, Nakato G et al. Segmented filamentous bacteria antigens presented by intestinal dendritic cells drive mucosal Th17 cell differentiation. Immunity 2014;40:594–607.

177 Ivanov I, Atarashi K, Manel N et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009;139:485–98.

178 Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 2014;146:1513–24.

179 Rahman K, Desai C, Iyer SS et al. Loss of junctional adhesion molecule a promotes severe steatohepatitis in mice on a diet high in saturated fat, fructose, and cholesterol. Gastroenterology 2016;151:733–46.e12.

180 Gabele E, Dostert K, Hofmann C et al. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol 2011;55:1391–9.

181 Craven L, Rahman A, Nair Parvathy S et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial. Am J Gastroenterol 2020;115:1055–65.

182 Juárez-Fernández M, Goikoetxea-Usandizaga N, Porras D et al. Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression. Hepatology 2023;77:1654–69.

183 Mouries J, Brescia P, Silvestri A et al. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J Hepatol 2019;71:1216–28.

184 Morrison MC, Gart E, Duyvenvoorde WV et al. Heat-inactivated Akkermansia muciniphila improves gut permeability but does not prevent development of non-alcoholic steatohepatitis in diet-induced obese Ldlr-/-Leiden mice. Int J Mol Sci 2022;23:2325.

185 Shi Z, Lei H, Chen G et al. Impaired intestinal Akkermansia muciniphila and aryl hydrocarbon receptor ligands contribute to nonalcoholic fatty liver disease in mice. mSystems 2021;6:e00985-20.

186 Li T, Lin X, Shen B et al. Akkermansia muciniphila suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6⁺ natural killer T cells. Front Immunol 2022;13:1047570.

187 He S, Cui S, Song W et al. Interleukin-17 weakens the NAFLD/ NASH process by facilitating intestinal barrier restoration depending on the gut microbiota. mBio 2022;13:e0368821.

188 Leonardi I, Gao IH, Lin WY et al. Mucosal fungi promote gut barrier function and social behavior via type 17 immunity. Cell 2022;185:831–846.e14.

189 Lee JS, Tato CM, Joyce-Shaikh B et al. Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability. Immunity 2015;43:727–38.

190 Zeng S, Rosati E, Saggau C et al. Candida albicans-specific Th17 cell-mediated response contributes to alcohol-associated liver disease. Cell Host Microbe 2023;31:389–404.e7.

191 Schneider KM, Bieghs V, Heymann F et al. CX3CR1 is a gatekeeper for intestinal barrier integrity in mice: limiting steatohepatitis by maintaining intestinal homeostasis. Hepatology 2015;62:1405–16.

192 Lingaiah S, Arffman RK, Morin-Papunen L et al. Markers of gastrointestinal permeability and dysbiosis in premenopausal women with PCOS: a case-control study. BMJ Open 2021;11:e045324.

193 Lindheim L, Bashir M, Münzker J et al. Alterations in gut microbiome composition and barrier function are associated with reproductive and metabolic defects in women with polycystic ovary syndrome (PCOS): a pilot study. PLoS One 2017;12:e0168390.

194 Paik D, Yao L, Zhang Y et al. Human gut bacteria produce T_H17-modulating bile acid metabolites. Nature 2022;603:907–12.

195 Hang S, Paik D, Yao L et al. Bile acid metabolites control T_H17 and T_reg cell differentiation. Nature 2019;576:143–8.

196 Kleinridders A, Schenten D, Könner AC et al. MyD88 signaling in the CNS is required for development of fatty acid-induced leptin resistance and diet-induced obesity. Cell Metab 2009;10:249–59.

197 Everard A, Geurts L, Caesar R et al. Intestinal epithelial MyD88 is a sensor switching host metabolism towards obesity according to nutritional status. Nat Commun 2014;5:5648.

198 Wen L, Ley RE, Volchkov PY et al. Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature 2008;455:1109–13.

199 Duparc T, Plovier H, Marrachelli VG et al. Hepatocyte MyD88 affects bile acids, gut microbiota and metabolome contributing to regulate glucose and lipid metabolism. Gut 2017;66:620–32.

200 Sun L, Xie C, Wang G et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med 2018;24:1919–29.

201 Rao Y, Kuang Z, Li C et al. Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis. Gut Microbes 2021;13:1–19.

202 Hu W, Gao W, Liu Z et al. Specific strains of Faecalibacterium prausnitzii ameliorate nonalcoholic fatty liver disease in mice in association with gut microbiota regulation. Nutrients 2022;14:2945.

203 Juarez-Fernandez M, Porras D, Petrov P et al. The synbiotic combination of Akkermansia muciniphila and quercetin ameliorates early obesity and NAFLD through gut microbiota reshaping and bile acid metabolism modulation. Antioxidants (Basel) 2021;10:2001.

204 Younossi ZM, Ratziu V, Loomba R et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2019;394:2184–96.

205 Clifford BL, Sedgeman LR, Williams KJ et al. FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. Cell Metab 2021;33:1671–1684.e4.

206 Wang W, Zhao J, Gui W et al. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease. Br J Pharmacol 2018;175:469–84.

207 Sun L, Pang Y, Wang X et al. Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters. Acta Pharm Sin B 2019;9:702–10.

208 Ou H, Fu Y, Liao W et al. Association between smoking and liver fibrosis among patients with nonalcoholic fatty liver disease. Can J Gastroenterol Hepatol 2019;2019:6028952.

209 Jung HS, Chang Y, Kwon MJ et al. Smoking and the risk of non-alcoholic fatty liver disease: a cohort study. Am J Gastroenterol 2019;114:453–63.

210 Wang L, Zhou J, Gober HJ et al. Alterations in the intestinal microbiome associated with PCOS affect the clinical phenotype. Biomed Pharmacother 2021;133:110958.

211 Zhang J, Sun Z, Jiang S et al. Probiotic Bifidobacterium lactis V9 regulates the secretion of sex hormones in polycystic ovary syndrome patients through the gut-brain axis. mSystems 2019;4:00017-19.

212 Maldonado-Gomez MX, Martínez I, Bottacini F et al. Stable engraftment of Bifidobacterium longum AH1206 in the human gut depends on individualized features of the resident microbiome. Cell Host Microbe 2016;20:515–26.

213 De La Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V et al. Metformin is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several shortchain fatty acid-producing microbiota in the gut. Diabetes Care 2017;40:54–62.

214 Han Q, Wang J, Li W et al. Androgen-induced gut dysbiosis disrupts glucolipid metabolism and endocrinal functions in polycystic ovary syndrome. Microbiome 2021;9:101.

215 Li T, Zhang T, Gao H et al. Tempol ameliorates polycystic ovary syndrome through attenuating intestinal oxidative stress and modulating of gut microbiota composition-serum metabolites interaction. Redox Biol 2021;41:101886.

216 Duan Y, Llorente C, Lang S et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature 2019;575:505–11.

217 Kim HJ, Vazquez Roque MI, Camilleri M et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005;17:687–96.

218 Mencarelli A, Cipriani S, Renga B et al. VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. PLoS One 2012;7:e45425.

219 Jena PK, Sheng L, Li Y et al. Probiotics VSL#3 are effective in reversing non-alcoholic steatohepatitis in a mouse model. Hepatobiliary Surg Nutr 2020;9:170–82.

220 Alisi A, Bedogni G, Baviera G et al. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2014;39:1276–85.

221 Wang Y, Wang Z, Wan Y et al. Assessing the in vivo ameliorative effects of Lactobacillus acidophilus KLDS1.0901 for induced non-alcoholic fatty liver disease treatment. Front Nutr 2023;10:1147423.

222 Hendrikx T, Duan Y, Wang Y et al. Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice. Gut 2019;68:1504–15.

223 Traussnigg S, Schattenberg JM, Demir M et al. Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. Lancet Gastroenterol Hepatol 2019;4:781–93.

224 Yu H, Zhao T, Liu S et al. MRGPRX4 is a bile acid receptor for human cholestatic itch. Elife 2019;8:e48431.

225 Troisi G, Crisciotti F, Gianturco V et al. The treatment with ursodeoxycholic acid in elderly patients affected by NAFLD and metabolic syndrome: a case-control study. Clin Ter 2013;164:203–7.

226 Lindor KD, Kowdley KV, Heathcote EJ et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004;39:770–8.

227 Marchiano S, Biagioli M, Roselli R et al. Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling. Biochim Biophys Acta Mol Cell Biol Lipids 2022;1867:159218.

228 Traussnigg S, Schattenberg JM, Demir M et al. norUrsodeoxycholic acid (norUDCA) improves non-alcoholic fatty liver disease (NAFLD): results from a randomized placebo-controlled, double-blind phase IIa study. Hepatology 2017;66:106A–8.

229 Roth JD, Feigh M, Veidal SS et al. INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy- confirmed non-alcoholic steatohepatitis. World J Gastroenterol 2018;24:195–210.

230 Hernandez ED, Zheng L, Kim Y et al. Tropifexor-mediated abrogation of steatohepatitis and fibrosis is associated with the antioxidative gene expression profile in rodents. Hepatol Commun 2019;3:1085–97.

231 Tully DC, Rucker PV, Chianelli D et al. Discovery of tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH). J Med Chem 2017;60:9960–73.

232 Sanyal AJ, Lopez P, Lawitz EJ et al. Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial. Nat Med 2023;29:392–400.

233 Anfuso B, Tiribelli C, Adorini L et al. Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model. Sci Rep 2020;10:1699.

234 Van Wagner LB, Koppe SWP, Brunt EM et al. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol 2011;10:277–86.

235 Zein CO, Yerian LM, Gogate P et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011;54:1610–9.

236 Russell BJ, Brown SD, Siguenza N et al. Intestinal transgene delivery with native E. coli chassis allows persistent physiological changes. Cell 2022;185:3263–77.e15.

237 Jin M, Chen J, Zhao X et al. An engineered lambda phage enables enhanced and strain-specific killing of enterohemorrhagic Escherichia coli. Microbiol Spectr 2022;10:e0127122.

238 Isabella VM, Ha BN, Castillo MJ et al. Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat Biotechnol 2018;36:857–64.

239 Puurunen MK, Vockley J, Searle SL et al. Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study. Nat Metab 2021;3:1125–32.

240 Lynch JP, Goers L, Lesser CF. Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics. Trends Pharmacol Sci 2022;43:772–86.

241 Kastl AJ Jr, Terry NA, Wu GD et al. The structure and function of the human small intestinal microbiota: current understanding and future directions. Cell Mol Gastroenterol Hepatol 2020;9:33–45.

242 James KR, Gomes T, Elmentaite R et al. Distinct microbial and immune niches of the human colon. Nat Immunol 2020;21:343–53.

243 Shalon D, Culver RN, Grembi JA et al. Profiling the human intestinal environment under physiological conditions. Nature 2023;617:581–91.

244 Le Chatelier E, Nielsen T, Qin J et al. Richness of human gut microbiome correlates with metabolic markers. Nature 2013;500:541–6.

245 Uusitupa HM, Rasinkangas P, Lehtinen MJ et al. Bifidobacterium animalis subsp. lactis 420 for metabolic health: review of the research. Nutrients 2020;12:892.

246 Wang J, Tang H, Zhang C et al. Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice. ISME J 2015;9:1–15.

247 Verdam FJ, Fuentes S, de Jonge C et al. Human intestinal microbiota composition is associated with local and systemic inflammation in obesity. Obesity (Silver Spring) 2013;21:E607–15.

248 Wang K, Liao M, Zhou N et al. Parabacteroides distasonis alleviates obesity and metabolic dysfunctions via production of succinate and secondary bile acids. Cell Rep 2019;26:222–35.e5.

249 Yang J, Li Y, Wen Z et al. Oscillospira - a candidate for the next-generation probiotics. Gut Microbes 2021;13:1987783.

250 Konikoff T, Gophna UO. A central, enigmatic component of the human gut microbiota. Trends Microbiol 2016;24:523–4.

251 Barrow F, Khan S, Fredrickson G et al. Microbiota-driven activation of intrahepatic B cells aggravates NASH through innate and adaptive signaling. Hepatology 2021;74:704–22.